Akamis Bio welcomes Andrew Hirsch to its Board of Directors

– USA, MA –  Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy platform to deliver novel immunotherapeutic payloads to solid tumors, announced the appointment of Andrew Hirsch to its Board of Directors.…

Talent4Boards
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.